MARKET

CVKD

CVKD

Cadrenal Therape
NASDAQ
1.510
+0.060
+4.14%
Closed 16:38 11/12 EST
OPEN
1.410
PREV CLOSE
1.450
HIGH
1.560
LOW
1.360
VOLUME
184.49K
TURNOVER
0
52 WEEK HIGH
13.01
52 WEEK LOW
0.8163
MARKET CAP
5.39M
P/E (TTM)
-0.3067
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CVKD last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at CVKD last week (1026-1030)?
Weekly Report · 11/02 09:16
Weekly Report: what happened at CVKD last week (1019-1023)?
Weekly Report · 10/26 09:16
Weekly Report: what happened at CVKD last week (1012-1016)?
Weekly Report · 10/19 09:16
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/13 17:06
Weekly Report: what happened at CVKD last week (1005-1009)?
Weekly Report · 10/12 09:17
Cadrenal Therapeutics Begins Strategic Review of Orphan Portfolio
TipRanks · 10/07 13:47
Cadrenal Therapeutics Begins Strategic Review Following FDA Alignment On CAD-1005
NASDAQ · 10/07 12:24
More
About CVKD
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.

Webull offers Cadrenal Therapeutics Inc stock information, including NASDAQ: CVKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVKD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CVKD stock methods without spending real money on the virtual paper trading platform.